Influence of gastric acid on gastric emptying and gastric distension‐induced pain response in rats – effects of famotidine and mosapride

Keto, Yoshihiro; Hirata, Tetsuya; Takemoto, Yukihiro; Yamano, Michiyo; Yokoyama, Toshihide

doi:10.1111/j.1365-2982.2011.01809.x

Cited by 9 publications

(7 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The T 50 values in rats and dogs are consistent with those reported for humans (8–25 min range) . Although several studies have demonstrated that pentagastrin delays the gastric emptying in rats and dogs, we observed no significant changes in the GET in this study. This discrepancy may be explained by the differences in dosage and administration route, as gastric emptying was significantly delayed by the intraperitoneal administration of pentagastrin at a high dose, in a preliminary study using rats (data not shown).…”

Section: Discussionsupporting

confidence: 90%

Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion

Kosugi

Yamamoto

Sano

et al. 2015

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion

Kosugi

Yamamoto

Sano

et al. 2015

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…Mosapride is available as a prokinetic agent in many Asian countries. Preclinical and clinical studies provided evidence for mosapride as a useful therapy for FD by showing its stimulating effect on gastric emptying, gastric accommodation and gastric motility in rats and healthy subjects . Thus far, no mechanistic studies in FD patients have been performed.…”

Section: Current Treatment Options For Functional Dyspepsiamentioning

confidence: 99%

Review article: treatment options for functional dyspepsia

Masuy

Oudenhove

Tack

2019

Aliment Pharmacol Ther

124

View full text Add to dashboard Cite

Background: Functional dyspepsia, consisting of epigastric pain syndrome and postprandial distress syndrome, is a prevalent functional gastrointestinal disorder. To date, only limited treatment options are available and conflicting results in terms of efficacy have been reported. Consequently, nonpharmacological treatment options are increasingly being explored for functional dyspepsia. Aim: To provide an overview of current pharmacological and nonpharmacological treatment options for functional dyspepsia. Methods: A literature search was conducted on Pubmed and other sources to identify relevant studies.Results: Acid suppressive therapy reduced symptoms in 30%-70% of the patients, with higher benefit in epigastric pain syndrome and superior effectiveness for proton pump inhibitors compared to H 2 -antagonists. Prokinetic agents, primarily used to treat postprandial distress syndrome, showed variable efficiency: 59%-81% responder rate for dopamine receptor antagonists, 32%-91% for serotonin-4-receptor agonists and 31%-80% for muscarinic receptor antagonists. H Pylori eradication, recommended in infected patients, was effective in 24%-82%. Refractory symptoms are addressed with neuromodulators. However, their efficacy in functional dyspepsia remains incompletely elucidated, available data showing symptom reduction in 27%-71% of the patients. Regarding herbal agents, peppermint oil reduced symptoms in 66%-91%, rikkunshito in 29%-34% and iberogast in 20%-95%. Lastly, acupuncture, cognitive behavioural therapy and hypnotherapy may help to provide symptom control, but research on their efficacy remains sparse.Conclusions: None of the available therapies is effective in the majority of patients without being associated with major side effects. Developing new treatment options is challenging due to the heterogeneity of functional dyspepsia, the lack of readily identified target mechanisms and the poor association between pathophysiological disturbances and symptoms.

show abstract

“…In that study, while pentagastrin-induced gastric acid hyper-secretion aggravated the pain response to gastric dilation by delaying gastric emptying, the histamine H2 blocker famotidine, but not the prokinetic drug mosapride, successfully ameliorated the pain response. 33 Several limitations associated with the present study warrant mention. First, regarding the illness period, we defined dyspeptic symptoms lasting for more than 1 month as FD.…”

Section: Discussionmentioning

confidence: 88%

Efficacy of acotiamide on postprandial distress syndrome and epigastric pain syndrome depending on the estimated gastric acid secretion level

Suzuki

Ohba

Kataoka

et al. 2022

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

Influence of gastric acid on gastric emptying and gastric distension‐induced pain response in rats – effects of famotidine and mosapride

Cited by 9 publications

References 54 publications

Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion

Evaluation of Acid Tolerance of Drugs Using Rats and Dogs Controlled for Gastric Acid Secretion

Review article: treatment options for functional dyspepsia

Efficacy of acotiamide on postprandial distress syndrome and epigastric pain syndrome depending on the estimated gastric acid secretion level

Contact Info

Product

Resources

About